Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3036656 Combinations in Rifampicin-susceptible Pulmonary Tuberculosis
NCT05382312Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ganfeborole in pulmonary tuberculosis (TB) (10 arms), sponsored by GSK. Primary endpoint: Change From Baseline in log10 Colony Forming Units (CFU) of Mycobacterium Tuberculosis (MTB) at Day 14. Started Jul 2022; status: completed.
02
Drugs
ganfeborole
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT05382312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382312.